Genocea Revamps Business, Market Reacts with 77 Percent Stock Price Drop

Genocea Biosciences took a massive hit to its stock on Tuesday following the news of a readjustment to their business focus.
On Monday (September 25) after the markets had closed Genocea Biosciences (NASDAQ:GNCA) shared its decision to completely revamp their business plans and enter the immuno-oncology sector to develop cancer vaccines. The market was less excited on Genocea’s decision to cut about 35 employees and move away from a phase 3 candidate.
This move comes at the cost of dropping the development of their genital herpes treatment GEN-003 and a layoff announcement, which will leave the company with 55 employees according to a report by MarketWatch.
“The sharp reduction in headcount reflects the fact Genocea no longer needs the team it put together to take GEN-003 through the clinic as it won’t spend any more money on the program,” FierceBiotech wrote.
Genocea expects to save 6.5 million approximately after the layoffs are completed. However, severance costs will total $1.1 million. All of these transactions will take place during the third quarter of the company.
“To our teammates who’ve given so much to advance GEN-003, we offer our profound thanks for their dedication,” president and chief executive officer of Genocea Chip Clark said in the company’s announcement. “We see this strategic process, which is already underway, as the best way to drive to commercial launch of and maximize shareholder value from GEN-003.”
Market reaction
The market responded to Genocea’s plans with a massive 76.55 percent drop to its stock at the close on Tuesday (September 26). After hours trading showed its stock price had increased 7.20 percent to $1.34 as of 7:11 p.m. EST.
The company’s cancer pipeline includes GEN-009, which Genocea claims will get its own clinical trial during the first half of 2018, which will report data in 2019.
“GEN-009 is an adjuvanted peptide vaccine designed to direct a patient’s T cells to attack their tumor. Antigens in a patient’s vaccine are selected by Genocea’s proprietary ATLAS platform,” the company said.
The company, up until Monday, had seen a 29.37 percent increase to its stock on a year-to-date period. On Tuesday however, they are facing a 65.28 percent reduction.
According to the analyst data aggregator site TipRanks, two of the four analysts covering the company, Alan Carr at Needham & Company and Stephen Willey at Stifel, downgraded their rates and removed their price targets on Genocea’s stock. At the time of this writing, Phil Nadeau, managing director and biotech research analyst at Cowen had reiterated its target price of $10 for Genocea, alongside his “Buy” rating, on Monday.
Investor Takeaway
Genocea is taking a gamble shifting from a product seemingly ready to enter the late stages of clinical development with a positive upside into a novel area with a vaccine that will take time to develop. So far the market has taken a negative take on the news and decided to jump the ship on the stock.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Bryan Mc Govern, hold no investment interest in any of the companies mentioned.
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1827.54 | +0.47 | |
Silver | 21.15 | +0.03 | |
Copper | 3.74 | 0.00 | |
Palladium | 1879.51 | +6.50 | |
Platinum | 911.26 | +4.32 | |
Oil | 107.06 | +2.79 | |
Heating Oil | 4.24 | +0.02 | |
Natural Gas | 6.17 | -0.07 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.